Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models

Although botulinum neurotoxin serotype A (BoNT/A) products are common treatments for various disorders, there is only one commercial BoNT/B product, whose low potency, likely stemming from low affinity toward its human receptor synaptotagmin 2 (hSyt2), has limited its therapeutic usefulness. We expr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Adv
Autors principals: Elliott, Mark, Favre-Guilmard, Christine, Liu, Sai Man, Maignel, Jacquie, Masuyer, Geoffrey, Beard, Matthew, Boone, Christopher, Carré, Denis, Kalinichev, Mikhail, Lezmi, Stephane, Mir, Imran, Nicoleau, Camille, Palan, Shilpa, Perier, Cindy, Raban, Elsa, Zhang, Sicai, Dong, Min, Stenmark, Pål, Krupp, Johannes
Format: Artigo
Idioma:Inglês
Publicat: American Association for the Advancement of Science 2019
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6357751/
https://ncbi.nlm.nih.gov/pubmed/30746458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aau7196
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars